Back

FGL-1 binding to LAG-3 inhibits T cell activation via disruption of CD28 and TCR signaling

Nyovanie, S.; Hashem, A.; Kanshin, E.; Oltean, N.; Ueberheide, B.; Patskovsky, Y.; Krogsgaard, M.

2025-08-07 immunology
10.1101/2025.08.05.668721 bioRxiv
Show abstract

Lymphocyte-activation gene 3 (LAG-3) is known to suppress T cell receptor (TCR) signaling by disrupting CD4/CD8 coreceptor and Lck association in the absence of ligand binding. However, the impact of Fibrinogen-like protein 1 (FGL-1) binding in modulating LAG-3 mediated inhibition and its specific impact on CD28 costimulatory signaling remains unclear. This study investigates the role of LAG-3/FGL-1 interaction in modulating T cell activation. Using phosphoproteomics and confocal microscopy in LAG-3+ Jurkat cells, we demonstrated that LAG-3/FGL-1 interaction suppresses T cell activation by disrupting CD28-mediated recruitment of Lck, impairing its colocalization with CD28. Importantly, this inhibition occurs independently of CD4-bound Lck, indicating that LAG-3 ligand engagement targets both free and membrane-associated Lck pools. Consequently, this leads to suppressed phosphorylation of CD28 and TCR/CD3 signaling components, broadly attenuating downstream tyrosine phosphorylation and T cell effector functions. Our findings identify the CD28-Lck axis as a critical target of LAG-3/FGL-1 inhibitory pathway and provide a rationale for therapeutic strategies that reinvigorate CD28-Lck signaling to enhance anti-tumor immunity.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 2%
12.1%
2
eLife
5422 papers in training set
Top 7%
9.9%
3
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 10%
6.7%
4
Science Signaling
55 papers in training set
Top 0.1%
6.2%
5
iScience
1063 papers in training set
Top 2%
4.7%
6
Frontiers in Immunology
586 papers in training set
Top 2%
4.5%
7
The Journal of Immunology
146 papers in training set
Top 0.4%
3.8%
8
Journal of Experimental Medicine
106 papers in training set
Top 0.9%
3.6%
50% of probability mass above
9
Cellular & Molecular Immunology
14 papers in training set
Top 0.4%
3.6%
10
Journal of Cell Biology
333 papers in training set
Top 1%
3.5%
11
Cancer Immunology Research
34 papers in training set
Top 0.1%
3.5%
12
Scientific Reports
3102 papers in training set
Top 48%
2.3%
13
Nature Communications
4913 papers in training set
Top 47%
2.0%
14
PLOS Pathogens
721 papers in training set
Top 5%
1.8%
15
Oncogene
76 papers in training set
Top 1%
1.6%
16
mBio
750 papers in training set
Top 8%
1.6%
17
PLOS Biology
408 papers in training set
Top 12%
1.5%
18
Immunity
58 papers in training set
Top 3%
1.2%
19
JCI Insight
241 papers in training set
Top 5%
1.2%
20
European Journal of Immunology
57 papers in training set
Top 0.4%
1.2%
21
Cell Communication and Signaling
35 papers in training set
Top 0.8%
0.9%
22
Science Immunology
81 papers in training set
Top 2%
0.9%
23
EMBO reports
136 papers in training set
Top 6%
0.8%
24
Nature Immunology
71 papers in training set
Top 2%
0.8%
25
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.8%
26
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.8%
27
Science Advances
1098 papers in training set
Top 29%
0.8%
28
EMBO Reports
88 papers in training set
Top 0.6%
0.8%
29
Advanced Science
249 papers in training set
Top 21%
0.7%
30
Immunology
29 papers in training set
Top 1%
0.7%